Valeritas (NSDQ:VLRX) said today that it inked an exclusive distribution deal with Tritech Biomed to commercialize its V-Go wearable insulin delivery device designed for patients with Type 2 diabetes in Israel.
Through the deal, the Bridgewater, N.J.-based company said that Tritech Biomed will have rights to promote, market and sell the V-Go system to diabetes clinics and patients in the region.
Read the whole story on our sister site, Drug Delivery Business News
The post Valeritas inks Israeli distro deal with Tritech Biomed appeared first on MassDevice.
from MassDevice https://ift.tt/2uzyXBg
Cap comentari:
Publica un comentari a l'entrada